JP2016538288A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016538288A5 JP2016538288A5 JP2016530882A JP2016530882A JP2016538288A5 JP 2016538288 A5 JP2016538288 A5 JP 2016538288A5 JP 2016530882 A JP2016530882 A JP 2016530882A JP 2016530882 A JP2016530882 A JP 2016530882A JP 2016538288 A5 JP2016538288 A5 JP 2016538288A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- pharmaceutical composition
- ohepa
- hetre
- hode
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 150000003839 salts Chemical group 0.000 claims 9
- BFWYTORDSFIVKP-VAEKSGALSA-N 15(S)-HPETE Chemical compound CCCCC[C@H](OO)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O BFWYTORDSFIVKP-VAEKSGALSA-N 0.000 claims 7
- JDSRHVWSAMTSSN-BSZOFBHHSA-N 13-HPODE Chemical compound CCCCCC(OO)\C=C\C=C/CCCCCCCC(O)=O JDSRHVWSAMTSSN-BSZOFBHHSA-N 0.000 claims 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- YIYBQIKDCADOSF-ARJAWSKDSA-N cis-pent-2-enoic acid Chemical compound CC\C=C/C(O)=O YIYBQIKDCADOSF-ARJAWSKDSA-N 0.000 claims 2
- 150000004885 piperazines Chemical class 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361904600P | 2013-11-15 | 2013-11-15 | |
| US61/904,600 | 2013-11-15 | ||
| PCT/IB2014/003027 WO2015071766A1 (en) | 2013-11-15 | 2014-11-17 | Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019212877A Division JP6818851B2 (ja) | 2013-11-15 | 2019-11-26 | 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016538288A JP2016538288A (ja) | 2016-12-08 |
| JP2016538288A5 true JP2016538288A5 (enExample) | 2017-12-28 |
Family
ID=52669635
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016530882A Pending JP2016538288A (ja) | 2013-11-15 | 2014-11-17 | 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩 |
| JP2019212877A Expired - Fee Related JP6818851B2 (ja) | 2013-11-15 | 2019-11-26 | 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩 |
| JP2020218615A Pending JP2021073194A (ja) | 2013-11-15 | 2020-12-28 | 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019212877A Expired - Fee Related JP6818851B2 (ja) | 2013-11-15 | 2019-11-26 | 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩 |
| JP2020218615A Pending JP2021073194A (ja) | 2013-11-15 | 2020-12-28 | 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10017453B2 (enExample) |
| EP (3) | EP3546446A1 (enExample) |
| JP (3) | JP2016538288A (enExample) |
| CN (2) | CN109232278A (enExample) |
| ES (1) | ES2727387T3 (enExample) |
| WO (1) | WO2015071766A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016370626B2 (en) | 2015-12-18 | 2020-08-20 | Afimmune Limited | Compositions comprising 15-HEPE and methods of using the same |
| JP6759448B2 (ja) * | 2017-03-14 | 2020-09-23 | イビデン株式会社 | 植物賦活剤 |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
| US20220133669A1 (en) | 2020-10-30 | 2022-05-05 | Ds Biopharma Limited | Pharmaceutical compositions comprising 15-hetre and methods of use thereof |
| FR3148365A1 (fr) * | 2023-05-04 | 2024-11-08 | Pierre Fabre Dermo-Cosmetique | Oxylipines dans le traitement de la séborrhée et/ou de l’acné |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3055923A (en) * | 1960-03-25 | 1962-09-25 | Baxter Laboratories Inc | Fatty acid salts |
| IE47777B1 (en) | 1978-01-23 | 1984-06-13 | Efamol Ltd | Pharmaceutical and dietary composition comprising gamma-linolenic acids |
| WO1990014824A1 (en) | 1988-01-14 | 1990-12-13 | Anders Frithz | Use of essential fatty acids for the preparation of a drug for the treatment of eczema |
| GB9111900D0 (en) | 1991-06-03 | 1991-07-24 | Efamol Holdings | Fatty acid compositions |
| JPH05186342A (ja) | 1992-01-10 | 1993-07-27 | Fujirebio Inc | 免疫調節作用を併せもつ抗炎症剤 |
| US5807884A (en) * | 1992-10-30 | 1998-09-15 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
| GB9301446D0 (en) | 1993-01-26 | 1993-03-17 | Scotia Holdings Plc | Internal radiation damage |
| AU673700B2 (en) | 1993-01-27 | 1996-11-21 | Scotia Holdings Plc | Triglycerides |
| US5696166A (en) * | 1995-10-31 | 1997-12-09 | Yanni; John M. | Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders |
| WO1998012561A1 (en) * | 1996-09-20 | 1998-03-26 | Atherogenics, Inc. | Diagnostics for and mediators of inflammatory disorders |
| GB9715444D0 (en) | 1997-07-22 | 1997-09-24 | Scotia Holdings Plc | Therapeutic and dietary compositions |
| WO1999059964A1 (en) * | 1998-05-15 | 1999-11-25 | University Of Vermont | Novel analogs of 16-hydroxyeicosatetraenoic acid |
| JP2000191525A (ja) | 1998-12-25 | 2000-07-11 | Nof Corp | 皮膚外用剤組成物 |
| BR0015436A (pt) * | 1999-11-09 | 2002-07-16 | Alcon Inc | Sais de hidroxieicosatetraenoato, composições e métodos de uso no tratamento de distúrbios dos olhos secos |
| IL151299A0 (en) | 2000-02-16 | 2003-04-10 | Brigham & Womens Hospital | Aspirin-triggered lipid mediators |
| US20020188024A1 (en) | 2000-08-23 | 2002-12-12 | Chilton Floyd H. | Fatty acid-containing emulsion with increased bioavailability |
| DE10121252A1 (de) | 2001-04-30 | 2002-11-07 | Christos C Zouboulis | Behandlung der Akne |
| WO2004072013A1 (ja) * | 2003-02-14 | 2004-08-26 | Taisho Pharmaceutical Co.,Ltd. | ヒドロキシエイコサジエン酸化合物 |
| JP2005179211A (ja) | 2003-12-17 | 2005-07-07 | Idemitsu Kosan Co Ltd | 皮膚外用剤組成物 |
| WO2005063231A2 (en) | 2003-12-31 | 2005-07-14 | Igennus Limited | Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof |
| WO2005102309A2 (en) | 2004-04-26 | 2005-11-03 | Ltb4 Sweden Ab | In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration |
| US7666447B2 (en) | 2004-10-08 | 2010-02-23 | Pharmanutrients | Compositions including Krill extracts and conjugated linoleic acid and methods of using same |
| US7893106B2 (en) | 2004-11-19 | 2011-02-22 | Martek Biosciences, Corporation | Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same |
| CA2599112C (en) | 2005-02-14 | 2013-10-22 | Suntory Limited | Composition comprising dihomo-.gamma.-linolenic acid (dgla) as the active ingredient |
| TW200711649A (en) | 2005-06-17 | 2007-04-01 | Combinatorx Inc | Combination therapy for the treatment of immunoinflammatory disorders |
| JP2010500566A (ja) | 2006-08-08 | 2010-01-07 | テシス バイオサイエンス， インコーポレイテッド | 非アルコール性脂肪肝疾患（ｎａｆｌｄ）および非アルコール性脂肪性肝炎（ｎａｓｈ）のマーカーおよびその使用方法 |
| JP5101894B2 (ja) | 2007-01-15 | 2012-12-19 | サントリーホールディングス株式会社 | 高度不飽和脂肪酸及びこれを含有する脂質の製造方法 |
| GB0802116D0 (en) | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
| WO2009154230A1 (ja) | 2008-06-17 | 2009-12-23 | 持田製薬株式会社 | 非アルコール性脂肪肝炎の予防／改善・治療薬 |
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| GB0907601D0 (en) | 2009-05-01 | 2009-06-10 | Equateq Ltd | Novel methods |
| US10154977B2 (en) | 2011-03-25 | 2018-12-18 | The Brigham And Women's Hospital, Inc. | Anti-inflammatory particles |
| US20120264824A1 (en) | 2011-04-15 | 2012-10-18 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| RU2014119948A (ru) | 2011-10-19 | 2015-11-27 | Дигнити Сайенсиз Лимитед | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ DGLA И/ИЛИ 15-HETrE, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| CA2856715A1 (en) | 2011-11-29 | 2013-06-06 | Dignity Sciences Limited | Compositions comprising 20-carbon fatty acids and methods of making and using same |
| CN107050457A (zh) | 2012-01-06 | 2017-08-18 | 翁特拉制药公司 | 游离酸形式的ω‑3多不饱和脂肪酸的富含dpa组合物 |
| US20120264705A1 (en) * | 2012-01-26 | 2012-10-18 | Dignity Sciences Limited | Antimicrobial compositions comprising 15-hetre and methods of use thereof |
| US20130267598A1 (en) | 2012-02-23 | 2013-10-10 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same |
| EP2833740B1 (en) | 2012-04-04 | 2016-09-14 | Pronova BioPharma Norge AS | Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof |
| AU2013259503B2 (en) | 2012-05-10 | 2017-03-16 | Solutex Na Llc | Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors |
| WO2014022816A2 (en) | 2012-08-03 | 2014-02-06 | Dignity Sciences Limited | Pharmaceutical compositions comprising 15-hetre and methods of treating or preventing arthritis using same |
| GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| RU2685706C2 (ru) | 2014-01-10 | 2019-04-23 | Эфиммьюн Лимитед | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением |
| MX375328B (es) | 2014-06-04 | 2025-03-06 | Ds Biopharma Ltd | Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas |
| MA41120A (fr) | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| AU2016370626B2 (en) | 2015-12-18 | 2020-08-20 | Afimmune Limited | Compositions comprising 15-HEPE and methods of using the same |
| CN108778266A (zh) | 2016-01-07 | 2018-11-09 | Ds生物制药有限公司 | 包含二高γ亚麻酸（DGLA）的医药组合物和其用途 |
-
2014
- 2014-11-17 ES ES14843234T patent/ES2727387T3/es active Active
- 2014-11-17 CN CN201811061377.2A patent/CN109232278A/zh active Pending
- 2014-11-17 US US14/543,638 patent/US10017453B2/en not_active Expired - Fee Related
- 2014-11-17 WO PCT/IB2014/003027 patent/WO2015071766A1/en not_active Ceased
- 2014-11-17 CN CN201480071412.2A patent/CN105899485B/zh not_active Expired - Fee Related
- 2014-11-17 EP EP19157319.5A patent/EP3546446A1/en not_active Withdrawn
- 2014-11-17 EP EP14843234.7A patent/EP3068757B1/en active Active
- 2014-11-17 EP EP21159762.0A patent/EP3878835A1/en not_active Withdrawn
- 2014-11-17 JP JP2016530882A patent/JP2016538288A/ja active Pending
-
2017
- 2017-12-01 US US15/828,700 patent/US10544088B2/en not_active Expired - Fee Related
-
2019
- 2019-11-26 JP JP2019212877A patent/JP6818851B2/ja not_active Expired - Fee Related
- 2019-12-05 US US16/704,289 patent/US20200181064A1/en not_active Abandoned
-
2020
- 2020-12-28 JP JP2020218615A patent/JP2021073194A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2601127T3 (es) | Derivado de pirazol y su uso con fines médicos | |
| JP2014505733A5 (enExample) | ||
| JP2015057451A5 (enExample) | ||
| HRP20250119T1 (hr) | Kdm1a inhibitor i njegova primjena u terapiji | |
| JP2017505285A5 (enExample) | ||
| AR080491A1 (es) | Formulaciones orales y sales lipofilicas de metilnaltrexona | |
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| JP2013014622A5 (enExample) | ||
| JP2012255026A5 (enExample) | ||
| JP2015038135A5 (enExample) | ||
| HRP20171512T1 (hr) | Derivati betulina | |
| JP2016511753A5 (enExample) | ||
| PE20160550A1 (es) | Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
| JP2016510326A5 (enExample) | ||
| NZ720328A (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
| WO2014107730A3 (en) | Use of fatty acid niacin conjugates for treating diseases | |
| JP2015537009A5 (enExample) | ||
| JP2018537513A5 (enExample) | ||
| JP2015516419A5 (enExample) | ||
| RU2016112257A (ru) | Композиция для лечения гипертензии и/или фиброза | |
| JP2016515550A5 (enExample) | ||
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares |